CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

Abbott Medical Devices1 site in 1 country1,203 target enrollmentOctober 2011

ConditionsCarotid Artery Disease Stroke Amaurosis Fugax Transient Ischemic Attack (TIA)

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Carotid Artery Disease
Sponsor: Abbott Medical Devices
Enrollment: 1203
Locations: 1
Primary Endpoint: Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days)
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.

Registry

clinicaltrials.gov

Start Date

October 2011

End Date

March 2016

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Abbott Medical Devices

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject must be ≥ 18 years of age.
•Subject does not have any condition that limits their anticipated survival to less than 3 years.
•Subject or a legally authorized representative must provide written informed consent prior to any trial related procedure.
•Subjects with neurological symptoms within 180 days of the procedure and ≥ 70% stenosis of the common or internal carotid artery by ultrasound or ≥ 50% stenosis of the common or internal carotid artery by angiogram - OR-
•Subjects without neurological symptoms within 180 days of the procedure and ≥ 70% stenosis of the common or internal carotid artery by ultrasound or ≥ 60% stenosis of the common or internal carotid artery by angiogram.
•Subject with all the following target vessel characteristics:
•Discrete lesion in internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA).
•Vessel diameter ≥ 4.0 mm and ≤ 9.0 mm from reference or contralateral artery.
•Absence of excessive vessel tortuosity that would impede delivery of devices.
•Subject must agree not to participate in any other clinical trial for a period of 1 year following the index procedure.

Exclusion Criteria

•Subjects with anatomic or clinical conditions which make them at high risk for adverse events from carotid endarterectomy (CEA).
•Subject with Hgb \<10.g/dl or platelet count \< 125,000 µl or has heparin-associated thrombocytopenia. For subjects on Coumadin (Warfarin) and for subjects with a platelet or coagulation disorder: Has an international normalized ratio (INR) \> 1.
•Subject has active bleeding diathesis or coagulopathy or subject would refuse blood transfusions.
•Subject is currently on a list for major organ transplantation (i.e., heart, lung, liver, kidney) or is being evaluated for such.
•Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
•Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.

Outcomes

Primary Outcomes

Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days)

Time Frame: 0 to 365 days

Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Between 31 and 365 Days

Time Frame: 365 days

Secondary Outcomes

Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Symptomatic Status(365 days)
Death and All Stroke(30 Days)
Composite of Peri-procedural Death and Stroke by Symptomatic Status(30 days)
Composite of Peri-procedural Death and Stroke by Age(30 days)
Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Age(365 days)
Freedom From Clinically Driven Target Lesion Revascularization(365 days)
Clinical Success(30 days)